ReviewFrontiers in chemistry2019
New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites.
Review in Frontiers in chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 135 citations in OpenAlex.
- In Vitro Metabolism of ΔDrug testing and analysis · 2026Article
- How structural variations in synthetic cannabinoids affect their metabolism: A pilot study on the in vivo metabolism of 8 synthetic cannabinoid receptor agonists.Archives of toxicology · 2026Article
- Human Stem Cell-Derived Neurospheroids and a Multi-Assay Strategy Provide Brain Cytotoxicity New Insights from ADB-FUBIATA Exposure.Neurotoxicity research · 2026Article
- A Novel Workflow for Fast Elucidation of Drug Metabolites for Screening-Combining In Silico Metabolite Prediction With Trapped Ion Mobility QTOF-MS.Drug testing and analysis · 2026Article
- Physicochemical Characterization and Metabolites Identification of the Synthetic Cannabinoid MDMB-5'Br-PINACA UsingChemical research in toxicology · 2026Article
- In vitro and in vivo metabolism of the synthetic cannabinoid FUB-144: comprehensive phase I and II profiling using UHPLC-HRMS.Archives of toxicology · 2026Article
- Synthetic cannabinoid receptor agonists containing silicon: exploring the metabolic pathways of ADMB- and Cumyl-3TMS-PrINACA in human urine specimens and post mortem material compared to in vitro and in silico data.Archives of toxicology · 2026Article
- Data Hidden in Sewage: Advanced Methods for Identification and Quantification of Synthetic Cannabinoids in Urban Wastewater.Molecules (Basel, Switzerland) · 2026Review
- Deadly confusion of novel psychoactive substances: fatal outcome of ADB-BUTINACA mislabeled as 3',4'-methylenedioxy-α-pyrrolidinohexiophenone.Forensic toxicology · 2026Article
- A Fatal Case Involving Chronic Intravenous Use of Homemade Methcathinone Derived from Pseudoephedrine Tablets: Post-Mortem Concentrations, Health Risk, and Medicolegal Aspect.International journal of molecular sciences · 2025Article
- A Sensitive and Comprehensive LC-MS/MS Method for the Analysis of Hallucinogens, Synthetic Cathinones, and Synthetic Cannabinoids in Urine Samples.Journal of mass spectrometry : JMS · 2025Article
- Structure-metabolism relationships of 4-pentenyl synthetic cannabinoid receptor agonists using in vitro human hepatocyte incubations and high-resolution mass spectrometry.Archives of toxicology · 2025Article
- In vitro metabolism of Benzyl-4CN-BUTINACA and MDMB-4CN-BUTINACA using human hepatocytes and LC-QToF-MS analysis.Archives of toxicology · 2025Article
- In vitro metabolism study of ADB-P-5Br-INACA and ADB-4en-P-5Br-INACA using human hepatocytes, liver microsomes, and in-house synthesized references.Drug testing and analysis · 2025Article
- Metabolic profiling of the synthetic cannabinoid APP-CHMINACA (PX-3) as studied by in vitro and in vivo models.Forensic toxicology · 2025Article
- Identification of phase-I and phase-II metabolites and the metabolic pathway of the novel synthetic cannabinoid 5F-EDMB-PICA in vitro.Archives of toxicology · 2024Article
- QuEChERS Extraction and Simultaneous Quantification in GC-MS/MS of Hexahydrocannabinol Epimers and Their Metabolites in Whole Blood, Urine, and Oral Fluid.Molecules (Basel, Switzerland) · 2024Article
- Acute and subacute toxic effects of CUMYL-4CN-BINACA on male albino rats.Forensic toxicology · 2024Article
- An emerging trend in Novel Psychoactive Substances (NPSs): designer THC.Journal of cannabis research · 2024Review
- The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC-QTOF-MS and synthesized reference standards.Journal of analytical toxicology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic cannabinoids (SCs) were initially developed as pharmacological tools to probe the endocannabinoid system and as novel pharmacotherapies, but are now highly abused. This is a serious public health and social problem throughout the world and it is highly challenging to identify which SC was consumed by the drug abusers, a necessary step to tie adverse health effects to the new drug's toxicity. Two intrinsic properties complicate SC identification, their often rapid and extensive metabolism, and their generally high potency relative to the natural psychoactive Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.